天麻醒脑胶囊治疗血管性认知功能障碍临床观察

摘要

Objective To observe the improvement effect and toxic side effects of e Tianma Xingnao capsule in the treatment of vascular cognitive impairment (VCI).Method 121 cases of patients with VCI were randomly divided into treatment group (88 cases) which was treated with Tianma Xingnao capsule and control group (33 cases) which was treated with the Aniracetam capsule .The patients of both groups were assessed by the MoCA, the MMSE, the ADL-R, the CDR, the P300 and the safety index including the blood routine, the liver function and the kidney function were detected.After treatment of (90 ±7) days, the above contents should be determined again, the two results were compared.Results After treatment, there were significant improvements in the MoCA, the MMSE and the CDR of both the treatment group and the control group (P<0.05), while there were no significant differences between the two groups, comparing with the control group, the treatment group had a significant differences in the score of the ADL-R (P<0.05).The P300 did not change in both groups after therapy.The patients of the two groups had no significant differences in the blood routine, the liver function and the kidney function.Conclusion The Tianma Xingnao capsule can improve the cognitive impairment of the VCI patients, and it is safe at the end of treatment of (90 ±7) days.%目的：观察天麻醒脑胶囊对血管性认知功能障碍（ VCI）的改善作用及毒副作用。方法将121例血管性认知功能障碍（VCI）患者随机分成两组：天麻醒脑胶囊治疗组（88例）和茴拉西坦胶囊对照组（33例）；两组均进行蒙特利尔认知评估（MoCA）量表、简易智能状态检查（MMSE）量表、日常生活活动（ADL－R）量表、临床痴呆分级（CDR）量表、事件相关诱发电位（P300）及血常规、肝功能、肾功能测定。治疗（90±7）天时重新测定上述内容并加以对比。结果治疗组和对照组在治疗后的MoCA量表、MMSE量表、CDR量表均较治疗前有明显改善（P＜0．05），两组之间比较未见明显异常（P＞0．05）；治疗组治疗后ADL－R量表评分改善同对照组相比有明显差异（ P＜0．05）；两组患者治疗后P300数值比较未见明显差异；两组患者治疗后血常规、肝功能、肾功能检测同治疗前相比均未见明显异常（P＞0．05）。结论天麻醒脑胶囊可有效改善VCI患者的认知功能损害，在治疗（90±7）天时是安全的。